Flatulence
Leap Therapeutics Slashes 75% of Workforce, Ends Clinical Trial, Considers Strategic Options
Leap Therapeutics; workforce reduction; biotech layoffs; clinical trial; strategic alternatives; sirexatamab; FL-501; R&D wind down
Octagon Therapeutics Ceases Operations Due to R&D Challenges and Unresolved Biology Questions
Autoimmune disease biotech, B cell immunomodulator program, OCT50 program, Novo Nordisk alliance, Winding down operations, Unresolved biology challenges
MEI Pharma’s Leadership Shakeup: CEO and Medical Head Step Down Amidst Wind-Down Considerations
MEI Pharma, wind down, CEO, medical head, strategic alternatives